Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Adaptyx Biosciences

Request full access

Biowearable patch for continuous multi-analyte molecular monitoring

Menlo Park, United StatesFounded 2022Biotech & Life Sciences

About Adaptyx Biosciences

Adaptyx Biosciences, founded in 2022, is a biowearables company that spun out of over a decade of research at Stanford University and the Chan Zuckerberg Biohub. The founders include CEO Vijit Sabnis, Ph.D., and Chief Science Officer Alex Yoshikawa, Ph.D., who developed the technology during his doctoral studies in Chemical Engineering at Stanford. The company is headquartered in Menlo Park, California.

The firm is developing a biowearable platform for continuous, multi-analyte molecular monitoring. The core technology consists of a minimally invasive microneedle sensor patch that uses programmable, synthetic DNA-based molecular switches. These lab-made DNA bioreceptors are engineered to bind to specific target molecules with high sensitivity, undergoing a reversible structural change upon recognition. This mechanism allows for the real-time, continuous tracking of a wide array of biomarkers in the interstitial fluid, moving beyond glucose to include hormones, proteins, electrolytes, and drugs. By combining this molecular sensing with AI-powered analytics, the platform aims to convert data streams into actionable insights for patients and clinicians, enabling earlier detection of health trends and more timely interventions.

To accelerate the development of new biosensors, Adaptyx operates a "Molecular Switch Foundry" which integrates automated molecular design, parallelized screening, and AI-driven optimization, significantly reducing development timelines. The company's business model is focused on obtaining FDA clearance for initial clinical applications, with future plans to expand into broader health and wellness markets. Current applications in development include heart failure management, hormone optimization for fertility and endocrine health, critical care drug monitoring, and personalized wellness tracking. The company makes money by developing and commercializing this platform for various healthcare segments.

Adaptyx Biosciences has secured a total of $23 million in funding since its inception. A recent seed financing round raised $14 million, led by Interlagos with significant participation from Overwater Ventures, Starbloom Capital, Stanford University, and the Chan Zuckerberg Biohub, among others. This capital is intended to accelerate research and development, expand the pipeline of molecular switches, support clinical trials, and scale the company's team.

Source: Dealroom company data

At a glance

Status
Operational
Employees
19
Open positions
None listed
Dealroom signal
84.5/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Biomarkers, Chronic Disease, Health Diagnostics, Spinout, Wearable, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Oct 2025 $14M $56M Cantos Ventures · Interlagos Capital · Chan Zuckerberg Biohub · Overwater Ventures ↗
SPINOUT✓Other financing Jan 2022 $0 — Stanford University —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Adaptyx Biosciences website traffic

Latest recorded traffic for Adaptyx Biosciences is 6.9K monthly website visits, up 392.9% over the last three months. Adaptyx Biosciences's team grew 90% over the past year.

Latest monthly visits6.9K 3-month web change+392.9% 1-year team growth+90%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Adaptyx Biosciences in the Menlo Park ecosystem

Live from Dealroom

The Adaptyx Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed9 investors entered at this stage

  • Interlagos Capital
  • Cantos Ventures
  • Chan Zuckerberg Biohub
  • Overwater Ventures
  • Starbloom Capital
  • Seaside Ventures
  • Humba Ventures
  • Stanford University
  • Hyperlink Ventures
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States94.7%
🇮🇳 India5.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Adaptyx Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Adaptyx Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.